UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF

Inclusion Criteria: Adult in-patients (≥18 years) Laboratory confirmed CCHF infection by positive polymerase chain reaction (PCR) test within 5 days prior to randomisation Capacity to provide informed consent signed by study patient or legally acceptable representative (for illiterate individuals). Women of childbearing potential (WOCBP) and male patients who are sexually active with WOCBP must agree to use a highly effective method of contraception (as outlined in section 5.4 below) from the first administration of trial treatment, throughout trial treatment and for the duration outlined in trial protocol as well as addition 14 days for women and 7 days for men after the last dose of trial treatment. Severity Grading System (SGS) for CCHF - mild/moderate. Less than or equal to 7 days from onset of CCHF symptoms Willingness to participate in the full protocol Requirement to be hospitalised for treatment- Exclusion Criteria: Stage 4 severe chronic kidney disease or requiring dialysis (i.e., estimated glomerular filtration (eGFR) rate \<30 mL/min/1.73 m2) Pregnant or breast feeding Anticipated transfer to another hospital which is not a study site within 72 hours Known Allergy to any study medication Patients participating in another clinical trial of an investigational medicinal product (CTIMP) within the last 30 days. Previous intolerance of Favipiravir or Ribavirin Any participants deemed not suitable, based on investigators opinion. Patients taking the drug…